1-3 of 3
Donald W. Milligan, MD
Close
Sort by
Journal Articles

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).

Peter Hillmen, MB, ChB, PhD, John G. Gribben, MD, DSc, George A Follows, Donald W. Milligan, MD, MBChB, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, David Oscier, MD, Claire E. Dearden, MD, Daniel B. Kennedy, Andrew R. Pettitt, PhD, MRCPath, Amit Nathwani, MD, PhD, Dena Cohen, Walter M Gregory, Andy C. Rawstron, PhD, Colin R.W. Hayward, MBBS, Christopher Pocock
Journal: Blood
Blood (2009) 114 (22): 3428.
https://doi.org/10.1182/blood.V114.22.3428.3428
Published: 2009
Journal Articles

Prognostic Factors in Older AML Patients Receiving Intensive and Non-Intensive Therapy: Analysis of the UK AML11 and AML14 Trials.

Keith Wheatley, DPhil, Cassey L. Brookes, MSc, Robert K. Hills, DPhil, Anthony H. Goldstone, FRCP, Donald W. Milligan, MD, Archie G. Prentice, Anthony V. Moorman, PhD, Alan K. Burnett
Journal: Blood
Blood (2005) 106 (11): 674.
https://doi.org/10.1182/blood.V106.11.674.674
Published: 2005
Journal Articles

Modification or Dose or Treatment Duration Has No Impact on Outcome of AML in Older Patients: Preliminary Results of the UK NCRI AML14 Trial.

Alan K. Burnett, MD, Donald W. Milligan, MD, Archie G. Prentice, MB, Anthony H. Goldstone, MD, Mary F. McMullin, MD, Robert K. Hills, PhD, Keith Wheatley, PhD
Journal: Blood
Blood (2005) 106 (11): 543.
https://doi.org/10.1182/blood.V106.11.543.543
Published: 2005